Genetically engineered human umbilical cord-derived mesenchymal stromal cells expressing human interleukin-12 and in vitro growth inhibition against lung adenocarcinoma cells

Results: Adenoviral method showed superior results in transfection efficiency (63.6%), post-transfection cell viability (82.6%) and hIL-12 protein expression (1.2 x 107 pg/ml) and thus was selected for the downstream experiments. [...]the integrity of hUCMSC-IL12 remained unaffected by the transduction through examination of their surface markers and differentiation properties. [...]MSCs must possess a specific set of cell surface markers, e.g. cluster of differentiation (CD)73, CD90, CD105 and lack expression of CD14, CD34, CD45, CD19 and human leucocyte antigen-DR (HLA-DR). [...]MSCs must have the ability to differentiate in vitro into adipocytes, chondroblasts and osteoblasts.2 Lung cancer is the leading cause of cancer worldwide and it accounts for one third of all the cancer-related deaths.3 Non-small cell lung cancer (NSCLC) accounts for the majority of all the lung cancer cases and can be further classified into three types: squamous cell carcinoma, adenocarcinoma and large cell carcinoma.4 Out of the three types, adenocarcinoma is the most common type of lung cancer as it comprises around 40% of all lung cancers.